Home Biosimilar Antibodies Others Others Nesvacumab (Anti-ANGPT2)
For research use only. Not for use in humans.

Nesvacumab (Anti-ANGPT2)

Synonyms: ANGPT2,ANG-2

Nesvacumab (Anti-ANGPT2) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically targets the Tie2 receptor ligand Angiopoietin-2 (Ang2). It has potential antitumor activity. MW :150 KD.

Nesvacumab (Anti-ANGPT2)

Quality Control

Batch: Purity: 99% Protein concentration: 5.029mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Nesvacumab (Anti-ANGPT2) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically targets the Tie2 receptor ligand Angiopoietin-2 (Ang2). It has potential antitumor activity. MW :150 KD.
References

Product Details

CAS No. 1296818-77-3
Molecular Weight 144.86
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01688960 COMPLETED Drug: nesvacumab (REGN910/ SAR307746)|Drug: nesvacumab (REGN Solid Tumors Regeneron Pharmaceuticals 2012-10 PHASE1
NCT01271972 COMPLETED Drug: nesvacumab (REGN910/ SAR307746) Solid Tumors Regeneron Pharmaceuticals 2011-01 PHASE1

(data from https://clinicaltrials.gov, updated on 2015-03-17)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.